DE60043070D1 - Proteine-abgabe durch polare epithelzellen schichte - Google Patents

Proteine-abgabe durch polare epithelzellen schichte

Info

Publication number
DE60043070D1
DE60043070D1 DE60043070T DE60043070T DE60043070D1 DE 60043070 D1 DE60043070 D1 DE 60043070D1 DE 60043070 T DE60043070 T DE 60043070T DE 60043070 T DE60043070 T DE 60043070T DE 60043070 D1 DE60043070 D1 DE 60043070D1
Authority
DE
Germany
Prior art keywords
bioactive
epithelial cells
protein delivery
moiety
polar epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043070T
Other languages
German (de)
English (en)
Inventor
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
United States Department of Health and Human Services
Original Assignee
Genentech Inc
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, United States Department of Health and Human Services filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60043070D1 publication Critical patent/DE60043070D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60043070T 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte Expired - Lifetime DE60043070D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (1)

Publication Number Publication Date
DE60043070D1 true DE60043070D1 (de) 2009-11-12

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043070T Expired - Lifetime DE60043070D1 (de) 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte

Country Status (8)

Country Link
US (1) US7824695B1 (cg-RX-API-DMAC7.html)
EP (1) EP1242122B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003512441A (cg-RX-API-DMAC7.html)
AT (1) ATE444081T1 (cg-RX-API-DMAC7.html)
AU (1) AU784657B2 (cg-RX-API-DMAC7.html)
CA (1) CA2389302C (cg-RX-API-DMAC7.html)
DE (1) DE60043070D1 (cg-RX-API-DMAC7.html)
WO (1) WO2001030392A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE307208T1 (de) * 1997-07-11 2005-11-15 Us Gov Health & Human Serv Pseudomonas exotoxin-a-ähnliche chimerische immunogene
EP1242122B1 (en) 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
US7713737B2 (en) 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US7666991B2 (en) 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
US20090148401A1 (en) * 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP2010205A2 (en) * 2006-03-16 2009-01-07 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
AU7694594A (en) * 1993-09-06 1995-03-27 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
ATE307208T1 (de) * 1997-07-11 2005-11-15 Us Gov Health & Human Serv Pseudomonas exotoxin-a-ähnliche chimerische immunogene
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
EP1224290B1 (en) 1999-10-22 2006-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Disulfide conjugated cell toxins and methods of making and using them
EP1242122B1 (en) 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
DK1379550T3 (da) 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser

Also Published As

Publication number Publication date
EP1242122A2 (en) 2002-09-25
AU784657B2 (en) 2006-05-18
JP2003512441A (ja) 2003-04-02
WO2001030392A3 (en) 2002-07-11
WO2001030392A2 (en) 2001-05-03
CA2389302C (en) 2011-03-15
US7824695B1 (en) 2010-11-02
CA2389302A1 (en) 2001-05-03
AU1339201A (en) 2001-05-08
EP1242122B1 (en) 2009-09-30
ATE444081T1 (de) 2009-10-15
JP2012051939A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
Niedel et al. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
DK0817847T4 (da) IL-17-receptor
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DE68923990D1 (de) Zellen mit ausgestattener Antikörperspezifität.
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
ES2187946T3 (es) Uso de interleucina-15.
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
PT1331944E (pt) Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
DE69130457D1 (de) Peptidfragmente des env-proteins vom immunschwäche-virus der katze und ihre verwendung in der diagnostik
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
DK1196196T3 (da) Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
SE9604470D0 (sv) Transmembrane component of tight junction
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
BR9105717A (pt) Receptor poli-ig sintetico,complexos de receptor-anticorpo,sua producao e uso
WO2001059073A3 (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition